down arrow

Humacyte, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44486Q1031
USD
1.30
0.04 (3.17%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.261.33

52 Week

1.096.77
Valuation
Technical
Day's Volume

CASH

3.08 M

Shareholding (Mar 2025)

FII

4.35%

Held by 62 FIIs

DII

81.54%

Held by 21 DIIs

Promoter

0.35%

How big is Humacyte, Inc.?

22-Jun-2025

As of Jun 18, Humacyte, Inc. has a market capitalization of 361.43 million and reported net sales of 0.52 million with a net profit of -80.03 million over the last four quarters. Shareholder's funds are at -52.67 million, with total assets of 137.87 million.

As of Jun 18, Humacyte, Inc. has a market capitalization of 361.43 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.52 million, while the sum of net profit for the same period is -80.03 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -52.67 million, and total assets amount to 137.87 million.

Read More

What does Humacyte, Inc. do?

22-Jun-2025

Humacyte, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net profit of $37 million as of March 2025. It has a market cap of $361.43 million, with key metrics indicating it is currently loss-making and has a debt-to-equity ratio of 0.18.

Overview:<BR>Humacyte, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 37 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 361.43 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.18 <BR>Return on Equity: -333.22% <BR>Price to Book: 10.03<BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Humacyte, Inc. overvalued or undervalued?

25-Jun-2025

As of August 14, 2023, Humacyte, Inc. is overvalued and has deteriorated to a "does not qualify" rating due to negative profitability metrics, including a price-to-book ratio of 11.15 and a return on equity of -333.22%, while significantly underperforming the S&P 500 with a year-to-date return of -56.24%.

As of 14 August 2023, the valuation grade for Humacyte, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently overvalued, as evidenced by its price-to-book value of 11.15 and negative EV to EBITDA of -3.93, which highlight the lack of profitability and excessive valuation relative to its assets. Additionally, the return on capital employed (ROCE) stands at a staggering -261.68%, and return on equity (ROE) is at -333.22%, further underscoring the company's financial struggles.<BR><BR>In comparison to its peers, Humacyte's EV to EBITDA ratio of -3.93 is better than that of uniQure NV at -5.35 and Precigen, Inc. at -3.90, but still reflects a challenging environment for the company. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -56.24% compared to the index's 2.44%, reinforcing the notion that Humacyte is not a viable investment at its current valuation.

Read More

Is Humacyte, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Humacyte, Inc. is in a bearish trend with strong indicators, including negative MACD and moving averages, and has underperformed the S&P 500 significantly, with a year-to-date return of -64.55% compared to the index's 12.22%.

As of 2 September 2025, the technical trend for Humacyte, Inc. has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both weekly and monthly time frames, and the moving averages are bearish on a daily basis. Additionally, the KST and OBV indicators are bearish on both weekly and monthly time frames, while Bollinger Bands and Dow Theory also indicate a mildly bearish sentiment. <BR><BR>In terms of performance, Humacyte has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -64.55% compared to the S&P 500's 12.22%, and a one-year return of -66.48% versus 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 16.15% and Operating profit at -423.48% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.82
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 223 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

8.29

stock-summary
Return on Equity

-2,982.23%

stock-summary
Price to Book

55.11

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-38 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.96%
0%
-10.96%
6 Months
-50.19%
0%
-50.19%
1 Year
-69.41%
0%
-69.41%
2 Years
-51.13%
0%
-51.13%
3 Years
-58.73%
0%
-58.73%
4 Years
-87.49%
0%
-87.49%
5 Years
-86.63%
0%
-86.63%

Humacyte, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Humacyte, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Humacyte, Inc. has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both weekly and monthly time frames, and the moving averages are bearish on a daily basis. Additionally, the KST and OBV indicators are bearish on both weekly and monthly time frames, while Bollinger Bands and Dow Theory also indicate a mildly bearish sentiment. In terms of performance, Humacyte has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -64.55% compared to the S&P 500's 12.22%, and a one-year return of -66.48% versus 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
16.15%
EBIT Growth (5y)
-423.48%
EBIT to Interest (avg)
-13.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
55.91%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
11.15
EV to EBIT
-3.68
EV to EBITDA
-3.93
EV to Capital Employed
9.62
EV to Sales
408.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-261.68%
ROE (Latest)
-333.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 34 Schemes (13.76%)

Foreign Institutions

Held by 62 Foreign Institutions (4.35%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -40.00% vs 0.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -202.45% vs 276.08% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.90",
          "val2": "-21.40",
          "chgp": "-30.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "3.00",
          "chgp": "-16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.20",
          "val2": "64.70",
          "chgp": "-109.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.70",
          "val2": "36.80",
          "chgp": "-202.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-98,760.80%",
          "val2": "-44,843.30%",
          "chgp": "-5,391.75%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -34.21% vs -823.33% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-107.20",
          "val2": "-92.30",
          "chgp": "-16.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.30",
          "val2": "6.60",
          "chgp": "40.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-29.10",
          "val2": "-12.70",
          "chgp": "-129.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-148.70",
          "val2": "-110.80",
          "chgp": "-34.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.30
0.50
-40.00%
Operating Profit (PBDIT) excl Other Income
-27.90
-21.40
-30.37%
Interest
2.50
3.00
-16.67%
Exceptional Items
-6.20
64.70
-109.58%
Consolidate Net Profit
-37.70
36.80
-202.45%
Operating Profit Margin (Excl OI)
-98,760.80%
-44,843.30%
-5,391.75%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -40.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -202.45% vs 276.08% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-107.20
-92.30
-16.14%
Interest
9.30
6.60
40.91%
Exceptional Items
-29.10
-12.70
-129.13%
Consolidate Net Profit
-148.70
-110.80
-34.21%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -34.21% vs -823.33% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Humacyte, Inc. stock-summary
stock-summary
Humacyte, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."